However, for high-risk and metastatic GIST, we propose a treatment strategy that incorporates p53-targeted therapy into KIT/PDGFRA inhibitor regimens to overcome drug resistance. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.